Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210320 · ClinicalTrials.gov registry record · Phase 1
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
A Phase 1 study of Food Allergy and Food Hypersensitivity, sponsored by Insignis Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07210320 is a Phase 1 study of Food Allergy and Food Hypersensitivity that is actively recruiting participants, run by Insignis Therapeutics. The registered enrollment target is 30 participants, below the 962-participant average among 17 other Food Allergy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07210320, a Phase 1 study of Food Allergy and Food Hypersensitivity, is actively recruiting participants, sponsored by Insignis Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, two-part study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as a single dose of L-dipivefrin (IN-001) sublingual spray in healthy adults. For both parts of the study, participants will undergo at least 10 hours of fasting prior to dosing. Part 1 of the study focuses on IN-001 dose/formulation exploration in a small number of participants (N=6) to help select the most appropriate dose/formulation to be used in Part 2 of the study in a larger number of participants (N=24).
Conditions Studied
Interventions
- DRUG Epinephrine Auto-Injector 0.3 mg/0.3 mL
- DRUG Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle
- DRUG IN-001 9.06 mg Sublingual Spray
- DRUG IN-001 13.59 mg Sublingual Spray
Study Locations (1)
Missouri
- Washington University in St. Louis School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07210320
The ClinicalTrials.gov registry entry for NCT07210320 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 962-participant average among 17 other Food Allergy trials with a reported enrollment target (97% lower). The listed sponsor is Insignis Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Food Allergy appearing as the primary indexed condition, and to 4 interventions - of which Epinephrine Auto-Injector 0.3 mg/0.3 mL is the first listed.
NCT07210320 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT07210320 about?
NCT07210320 is a clinical study titled "PK/PD Study of IN-001 Sublingual Spray in Healthy Adults". This is an open-label, two-part study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as a single dose of L-dipivefrin (IN-001) sublingual spray in healthy adults. For both parts of the study, participants will undergo at least 10 hours of fasting prior to d...
What is the current status of trial NCT07210320?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-10-24. Estimated completion is 2026-03-31.
What conditions does trial NCT07210320 study?
This clinical trial studies the following conditions: Food Allergy, Food Hypersensitivity, Food Allergy Peanut, Anaphylaxis.
What interventions are being tested in trial NCT07210320?
The interventions under investigation include: Epinephrine Auto-Injector 0.3 mg/0.3 mL (DRUG), Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle (DRUG), IN-001 9.06 mg Sublingual Spray (DRUG), IN-001 13.59 mg Sublingual Spray (DRUG).
Who is sponsoring clinical trial NCT07210320?
This trial is sponsored by Insignis Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07210320 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
RECRUITING · Phase 1
-
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
COMPLETED · Phase 1
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
COMPLETED · Phase 1
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
-
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
RECRUITING
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.